SCHEMBL2725328

SCHEMBL2725328

N#Cc1c(N)nc2cc(Br)ccc2c1O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 1/20 0.45
KDM4E B2RXH2 5/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MAPK14 Q16539 2/20 0.39
ACHE P22303 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
BACE1 P56817 1/20 0.38
MPO P05164 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 2/20 0.37
GAA P10253 1/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24578777 0.84 MDM4 (0.40) MDM4KDM4ERXFP1MEN1KMT2A
SCHEMBL31636662 0.82 KDM4E (0.46) MDM4KDM4ERXFP1MEN1KMT2A
SCHEMBL31636725 0.78 KDM4E (0.56) KDM4ESMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL3518114 0.78 KDM4E (0.56) KDM4ESMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL6784397 0.77 KDM4E (0.47) KDM4ESMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL22233993 0.76 MPO (0.47) MEN1KMT2ANPC1RAB9AACHE
SCHEMBL6779214 0.75 KDM4E (0.53) KDM4ESMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL1414662 0.73 ADORA1 (0.39) MDM4KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL3455631 0.72 ALDH1A1 (0.39) KDM4ERXFP1MEN1KMT2AMPO
SCHEMBL25250436 0.71 KDM4E (0.36) MDM4KDM4ESMN1; SMN2RXFP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2635279-A2 CHEMICAL COMPOUNDS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-11 EP disclosed
US-20130225524-A1 Chemical Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2013-08-29 US disclosed
US-20130225524-A1 Chemical Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2013-08-29 US disclosed
US-20130225524-A1 Chemical Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2013-08-29 US disclosed
WO-2012061557-A2 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2012-05-10 WO disclosed
WO-2012061557-A2 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2012-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225524-A1 Chemical Compounds LDHA, NQO2, LDHB MDM4 2438/4885KDM4E 1541/4885SMN1; SMN2 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.